Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-07

Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of upadacitinib for giant cell arteritis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Giant Cell Arteritis (GCA) | Phase 3 | Status: COMPLETED | Results posted: 2025-03-07